{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:30:30Z","timestamp":1791174630386,"version":"4.1.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Nelarabine, a purine analog with T-cell specific action, has been approved for relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma (ALL\/LBL). This is a report of a single-arm phase 2 study conducted in adults (18-81 years of age) with relapsed\/refractory T-ALL\/LBL. After 1 or 2 cycles, 45 of 126 evaluable patients (36%) achieved complete remission (CR), 12 partial remission (10%), and 66 (52%) were refractory. One treatment-related death was observed, and 2 patients were withdrawn before evaluation. A total of 80% of the CR patients were transferred to stem cell transplantation (SCT). Overall survival was 24% at 1 year (11% at 6 years). After subsequent SCT in CR, survival was 31% and relapse-free survival 37% at 3 years. Transplantation-related mortality was 11%. Neurologic toxicities of grade I-IV\/grade III-IV were observed in 13%\/4% of the cycles and 16%\/7% of the patients. This largest study so far with nelarabine in adults showed impressive single-drug activity in relapsed T-ALL\/T-LBL. The drug was well tolerated, even in heavily pretreated patients. A high proportion of CR patients were transferred to SCT with low mortality but a high relapse rate. Exploration of nelarabine in earlier stages of relapse (eg, increasing minimal residual disease), in front-line therapy, and in combination is warranted.<\/jats:p>","DOI":"10.1182\/blood-2011-01-329441","type":"journal-article","created":{"date-parts":[[2011,6,29]],"date-time":"2011-06-29T09:28:54Z","timestamp":1309339734000},"page":"3504-3511","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":160,"title":["High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation"],"prefix":"10.1182","volume":"118","author":[{"given":"Nicola","family":"G\u00f6kbuget","sequence":"first","affiliation":[{"name":"Department of Medicine II, Hematology\/Oncology, Goethe University Hospital, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadezda","family":"Basara","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital, Leipzig, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herrad","family":"Baurmann","sequence":"additional","affiliation":[{"name":"Center for Bone Marrow Transplantation, Deutsche Klinik f\u00fcr Diagnostik, Wiesbaden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Beck","sequence":"additional","affiliation":[{"name":"Department of Medicine II, University Hospital, Mainz, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Br\u00fcggemann","sequence":"additional","affiliation":[{"name":"University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Diedrich","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Medizinische Hochschule, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"G\u00fcldenzoph","sequence":"additional","affiliation":[{"name":"Department of Medicine II, University Hospital Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Hartung","sequence":"additional","affiliation":[{"name":"Internal Medicine II, Klinikum Oldenburg, Hematology\/Oncology, Oldenburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-August","family":"Horst","sequence":"additional","affiliation":[{"name":"University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"H\u00fcttmann","sequence":"additional","affiliation":[{"name":"Center for Internal Medicine, Department of Hematology, University Hospital, Essen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kobbe","sequence":"additional","affiliation":[{"name":"Department for Hematology\/Oncology, University Hospital, D\u00fcsseldorf, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Naumann","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Carl Gustav Carus University, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ratei","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, HELIOS Klinikum Berlin Buch, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Reichle","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, University Hospital, Regensburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Hematology\/Oncology, Goethe University Hospital, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"Internal Medicine A, University Hospital, M\u00fcnster, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Viardot","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Wattad","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Kliniken Essen S\u00fcd, Essen-Werden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Hoelzer","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Hematology\/Oncology, Goethe University Hospital, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111807110350400_B1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/j.seminhematol.2008.09.003","article-title":"Treatment of adult acute lymphoblastic leukemia.","volume":"46","author":"G\u00f6kbuget","year":"2009","journal-title":"Semin Hematol"},{"issue":"21","key":"2019111807110350400_B2","first-page":"324","article-title":"Successful subtype oriented treatment strategies in adult T-ALL: results of 744 patients treated in three consecutive GMALL studies [abstract].","volume":"114","author":"Hoelzer","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"25","key":"2019111807110350400_B3","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","article-title":"T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993).","volume":"114","author":"Marks","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111807110350400_B4","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL12\/ECOG 2993 study.","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2019111807110350400_B5","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial.","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"2019111807110350400_B6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group.","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"issue":"15","key":"2019111807110350400_B7","first-page":"3352","article-title":"2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies.","volume":"55","author":"Lambe","year":"1995","journal-title":"Cancer Res"},{"issue":"4","key":"2019111807110350400_B8","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood.V61.4.660.bloodjournal614660","article-title":"Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells.","volume":"61","author":"Cohen","year":"1983","journal-title":"Blood"},{"issue":"8","key":"2019111807110350400_B9","first-page":"3646","article-title":"Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.","volume":"45","author":"Verhoef","year":"1985","journal-title":"Cancer Res"},{"issue":"15","key":"2019111807110350400_B10","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2005.03.199","article-title":"Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies.","volume":"23","author":"Kurtzberg","year":"2005","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111807110350400_B11","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111807110350400_B12","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"issue":"24","key":"2019111807110350400_B13","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1200\/JCO.2007.11.5253","article-title":"Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome.","volume":"25","author":"Baldus","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111807110350400_B14","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"issue":"6","key":"2019111807110350400_B15","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-006-0328-0","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates.","volume":"59","author":"Berg","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2019111807110350400_B16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/pbc.20550","article-title":"Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.","volume":"47","author":"Raetz","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2019111807110350400_B17","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1080\/10428190701509772","article-title":"Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma?","volume":"48","author":"Uyttebroeck","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2019111807110350400_B18","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1002\/cncr.23919","article-title":"Outcome of adults with acute lymphocytic leukemia after second salvage therapy.","volume":"113","author":"O'Brien","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"2019111807110350400_B19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.","volume":"27","author":"Bader","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111807110350400_B20","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1182\/blood.V92.11.4072","article-title":"Minimal residual disease statues before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia.","volume":"92","author":"Knechtli","year":"1998","journal-title":"Blood"},{"issue":"8","key":"2019111807110350400_B21","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/ajh.21719","article-title":"Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient.","volume":"85","author":"Papayannidis","year":"2010","journal-title":"Am J Hematol"},{"issue":"11","key":"2019111807110350400_B22","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.1998.16.11.3607","article-title":"Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response.","volume":"16","author":"Gandhi","year":"1998","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111807110350400_B23","first-page":"1135","article-title":"Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.","volume":"3","author":"Cooper","year":"2007","journal-title":"Ther Clin Risk Manag"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/13\/3504\/1344382\/zh803911003504.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/13\/3504\/1344382\/zh803911003504.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T12:13:40Z","timestamp":1574079220000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/13\/3504\/29292\/High-singledrug-activity-of-nelarabine-in-relapsed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,29]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2011,9,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-01-329441","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,29]]}}}